Research programme: antibody-drug conjugates - Ambrx/Sevion Therapeutics

Drug Profile

Research programme: antibody-drug conjugates - Ambrx/Sevion Therapeutics

Latest Information Update: 03 Dec 2014

Price : $50

At a glance

  • Originator Ambrx; Fabrus
  • Class Antibodies; Drug conjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 17 Nov 2014 No development reported for Undefined indication in USA (unspecified route)
  • 09 Sep 2014 Senesco Technologies changes name to Sevion Therapeutics
  • 03 Jul 2014 Early research is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top